FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were…